Tempus AI, Inc. Class A Common Stock logo

Tempus AI, Inc. Class A Common Stock(TEM)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
SELL
SELL for 1 day
PROFIT SINCE LAST BUY
-19.59% ▼
LAST CLOSE
$64.76
11/16/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for TEM

11/16/2026: TEM (1-star) is a SELL. SELL for 1 day. Simulated Profits (-19.59%). Updated daily EoD!

Tempus AI is a healthcare technology company that combines molecular diagnostic testing with artificial intelligence to advance precision medicine. The company exhibits strong revenue growth driven by expanding diagnostic volumes and high-margin data-licensing agreements with life sciences partners. Its primary investment thesis centers on scaling its proprietary multimodal data platform to transform clinical decision-making and drug discovery. However, key risks include ongoing net losses, high stock-based compensation, and intense competition in the healthcare analytics space. The stock suits growth-oriented investors willing to tolerate high volatility while monitoring bottom-line margin improvement and regulatory developments.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitTempus delivers rapid top-line revenue expansion and operates at the intersection of high-growth healthcare technology and artificial intelligence.
Momentum investorStrong fit while signal remains positiveStrong quarterly revenue growth and high market interest make the stock attractive when technical and sentiment indicators trend upward.
Value investorWeak fitThe company currently registers net losses and trades on forward growth expectations rather than traditional value metrics.
Dividend investorWeak fitTempus does not pay dividends, opting instead to reinvest earnings into business expansion.
Low-risk investorWeak fitHigh share price volatility and ongoing bottom-line unprofitability expose investors to considerable risk.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock experiences significant price swings driven by market sentiment and growth expectations.
Valuation riskMedium / highPricing relies heavily on sustaining aggressive future revenue and margin expansion.
Competition risk (AI and healthcare data)Medium / highIntense competition from established healthcare data giants and diagnostic labs could pressure margins.
Business qualityMediumThe core platform demonstrates strong revenue retention and proprietary data scale, offset by net losses.
Dividend incomeLow / noneIncome-focused investors receive no dividend yield from the equity.
Execution riskMedium / highSuccessfully integrating recent acquisitions and scaling profitability requires precise operational management.

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 13.06B USD
Price to earnings Ratio -
1Y Target Price 89.56
Price to earnings Ratio -
1Y Target Price 89.56
Volume (30-day avg) 6.6M shares
Beta 3.61
52 Weeks Range 40.77 - 89.09
Updated Date 11/15/2026
52 Weeks Range 40.77 - 89.09
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.06

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
63.9%
Active BUY / eligible
69 / 108
30-Day BUY Count Change
+31
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Health Information Services

BUY participation
100.0%
Active BUY / eligible
4 / 4
30-Day BUY Count Change
+1

Eligible universe: 4 stocks.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit -48.13%
Avg. Invested days 19
Today’s Advisory SELL
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/16/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
TEM receives a 3-star rating, supported by solid company fundamentals, and solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
TEM has solid overall fundamentals (4 stars), with moderate financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+65.3%) and strong revenue growth (+83.4%) are partially offset by weak cash generation (FCF margin -19.3%), weak profitability (net margin -19.3%).

Financial Health Rating

★★★★★
TEM's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 34.9%). Cash strength is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is TEM's strongest growth driver at +83.4% FY2025 versus FY2024 (strong, 5 stars). By comparison, earnings growth (+65.3%, strong) is also strong, while free-cash-flow growth (-16.2%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 58.2% and approximately 70.9% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 37.11% supports management-shareholder alignment.

Top 5 Institutional Investors

ARK Investment Management LLC 5.49%
BlackRock Inc 4.55%
Baillie Gifford & Co Limited. 3.79%
SoftBank Group Corp 2.96%
JPMorgan Chase & Co 2.74%

Unit Economics (Per $1K Revenue)

★★★★★
TEM generates approximately $627 of gross profit, $-199 of operating income, and $-193 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 17.42%

Quantitative Style Profile

★★★★★
TEM has a large-cap, liquid profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

High VolatilityLarge / Mega Cap StabilityShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
DiagnosticsClinical molecular diagnostic testing services, including oncology profiling, hereditary cancer screening, and MRD tests.This segment generates the lion's share of total revenue through direct volume-based testing fees paid by healthcare providers and insurers.
Data and ApplicationsLicensing proprietary multimodal clinical databases (Insights) and providing software applications (Lens/Hub) to life sciences firms.This high-margin segment monetizes aggregated healthcare data to help pharmaceutical companies discover drugs and match patients to clinical trials.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 13.85B
Price to Sales(TTM) 8.65
Enterprise Value 13.85B
Price to Sales(TTM) 8.65
Enterprise Value to Revenue 9.18
Enterprise Value to EBITDA -
Shares Outstanding 177.36M
Shares Floating 125.67M
Shares Outstanding 177.36M
Shares Floating 125.67M
Percent Insiders 37.11
Percent Institutions 58.16

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.